Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Automated insulin delivery is the treatment of choice in adults with type 1 diabetes. Data are needed on the efficacy and safety of automated insulin delivery for children and youth with diabetes and elevated glycated hemoglobin levels.
Methods: In this multicenter, open-label randomized controlled trial, we assigned patients with type 1 diabetes in a 1:1 ratio either to use an automated insulin delivery system (MiniMed 780G) or to receive usual diabetes care of multiple daily injections or non--automated pump therapy (control). The patients were children and youth (defined as 7 to 25 years of age) with elevated glycemia (glycated hemoglobin ≥8.5% with no upper limit). The primary outcome was the baseline-adjusted between-group difference in glycated hemoglobin at 13 weeks.
Results: A total of 80 patients underwent randomization (37 to automated insulin delivery and 43 to control) and all patients completed the trial. At 13 weeks, the mean (±SD) glycated hemoglobin decreased from 10.5±1.9% to 8.1±1.8% in the automated insulin delivery group but remained relatively consistent in the control group, changing from 10.4±1.6% to 10.6±1.8% (baseline-adjusted between-group difference, -2.5 percentage points; 95% confidence interval [CI], -3.1 to -1.8; P<0.001). Patients in the automated insulin delivery group spent on average 8.4 hours more in the target glucose range of 70 to 180 mg/dl than those in the control group. One severe hypoglycemia event and two diabetic ketoacidosis events occurred in the control group, with no such events in the automated insulin delivery group.
Conclusions: In this trial of 80 children and youth with elevated glycated hemoglobin, automated insulin delivery significantly reduced glycated hemoglobin compared with usual diabetes care, without resulting in severe hypoglycemia or diabetic ketoacidosis events. (Funded by Lions Clubs New Zealand District 202F and others; Australian New Zealand Clinical Trials Registry number, ACTRN12622001454763.).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/EVIDoa2400185 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Clinical Impact of Using Personal Glucose Targets in a Hybrid Closed-Loop System Differs According to Age.
Diabetes Technol Ther
September 2025
Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, United Kingdom.
CamAPS FX is a customizable hybrid closed-loop app with a default target glucose of 105 mg/dL. The personal glucose target is user-adjustable in 1 mg/dL increments between 80 and 198 mg/dL in 30-min segments over 24 h. We assessed the impact of different personal glucose targets on glycemic control during real-world use of CamAPS FX in different age-groups.
View Article and Find Full Text PDFUnveiling the Metabolic Burden: A Clinicopathological Study of Chronic Plaque Psoriasis and Its Association With Metabolic Syndrome.
Cureus
August 2025
Department of Pathology, Mahatma Gandhi Memorial Medical College, Indore, IND.
Introduction Psoriasis is a chronic, immune-mediated inflammatory skin disease with systemic manifestations. Among its significant comorbidities, metabolic syndrome (MS) - a constellation of obesity, hypertension, dyslipidemia, and insulin resistance - has gained recognition due to its association with increased cardiovascular risk and reduced life expectancy. Chronic systemic inflammation, shared immunological pathways, and elevated pro-inflammatory cytokines are thought to underlie this association.
View Article and Find Full Text PDFValidation in diabetic rats of a fully automated insulin delivery system based on impulsive offset-free MPC control.
PLoS One
September 2025
Grupo GITA, Facultad de Minas, Universidad Nacional de Colombia, Medellín, Colombia.
The development of an impulsive automated insulin delivery system (i-AiDS) for type 1 diabetes mellitus aims to provide real-time blood glucose regulation with minimal human intervention. This study presents the validation of an offset-free impulsive zone model predictive control strategy designed to cope with external disturbances such as meal intake and plant-model mismatch in a diabetic rat model. Fourteen male Wistar rats induced diabetes with streptozotocin were monitored using an continuous glucose monitoring and regulated by delivering insulin with a customized low-cost pump.
View Article and Find Full Text PDFBlue Light Effect on Metabolic Changes in Induced Precocious Puberty in Rats.
Biology (Basel)
July 2025
Academy of Romanian Scientists, Ilfov 3, 050044 Bucharest, Romania.
Modern life, characterized by constant exposure to artificial light from electronic devices, such as light-emitting diodes (LEDs), disrupts the natural circadian rhythm and induces important metabolic changes. The impact of blue light exposure on male and female rat's onset of puberty, hormonal and biochemical parameters was assessed by comparison between the four study groups: the control group (CTRL) maintained under normal light conditions, the group exposed to blue light from a mobile phone (MP), the group subjected to blue light from a computer screen (PC), and the group exposed to blue light from an LED lamp (LED). Both female and male rats exposed to PC and LED failed to thrive, with a significantly lower body weight intake than the CTRL group.
View Article and Find Full Text PDFPost-exercise glycaemic control for 24 h: Fasted morning exercise with and without glucagon in adults with type 1 diabetes using automated insulin delivery.
Diabetes Obes Metab
September 2025
Steno Diabetes Center Copenhagen, Clinical and Translational Research, Diabetes Technology Research, Herlev, Denmark.